Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

A One Health overview, facilitating advances in comparative medicine and translational research.

Stroud C, Dmitriev I, Kashentseva E, Bryan JN, Curiel DT, Rindt H, Reinero C, Henry CJ, Bergman PJ, Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y, O'Connor D, Treml LS, Stannard JP, Cook JL, Jacobs M, Wyckoff GJ, Likins L, Sabbagh U, Skaff A, Guloy AS, Hays HD, LeBlanc AK, Coates JR, Katz ML, Lyons LA, Johnson GC, Johnson GS, O'Brien DP, Duan D, Calvet JP, Gandolfi B, Baron DA, Weiss ML, Webster DA, Karanu FN, Robb EJ, Harman RJ.

Clin Transl Med. 2016 Aug;5(Suppl 1):26. doi: 10.1186/s40169-016-0107-4.

2.

Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma.

Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y.

Clin Cancer Res. 2016 Sep 1;22(17):4380-90. doi: 10.1158/1078-0432.CCR-16-0088. Epub 2016 Mar 18.

3.

Assessment of canonical NF-κB activity in canine diffuse large B-cell lymphoma.

Gaurnier-Hausser A, Mason NJ.

Methods Mol Biol. 2015;1280:469-504. doi: 10.1007/978-1-4939-2422-6_29.

PMID:
25736768
4.

A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.

Habineza Ndikuyeze G, Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ, Flood P, Krick E, Propert KJ, Mason NJ.

PLoS One. 2014 May 5;9(5):e95404. doi: 10.1371/journal.pone.0095404. eCollection 2014.

5.

Evidence of an oncogenic gammaherpesvirus in domestic dogs.

Huang SH, Kozak PJ, Kim J, Habineza-Ndikuyeze G, Meade C, Gaurnier-Hausser A, Patel R, Robertson E, Mason NJ.

Virology. 2012 Jun 5;427(2):107-17. doi: 10.1016/j.virol.2012.02.013. Epub 2012 Mar 8.

6.

NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.

Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ, Mason NJ.

Clin Cancer Res. 2011 Jul 15;17(14):4661-71. doi: 10.1158/1078-0432.CCR-10-3310. Epub 2011 May 24.

7.

The immunomodulatory role of angiocidin, a novel angiogenesis inhibitor.

Gaurnier-Hausser A, Tuszynski GP.

Curr Pharm Des. 2009;15(17):1937-48.

PMID:
19519434
8.

The novel angiogenic inhibitor, angiocidin, induces differentiation of monocytes to macrophages.

Gaurnier-Hausser A, Rothman VL, Dimitrov S, Tuszynski GP.

Cancer Res. 2008 Jul 15;68(14):5905-14. doi: 10.1158/0008-5472.CAN-07-6179.

9.

Angiocidin promotes pro-inflammatory cytokine production and antigen presentation in multiple sclerosis.

Kremlev SG, Gaurnier-Hausser AL, Del Valle L, Perez-Liz G, Dimitrov S, Tuszynski G.

J Neuroimmunol. 2008 Feb;194(1-2):132-42. doi: 10.1016/j.jneuroim.2007.11.003. Epub 2008 Jan 22.

PMID:
18207252

Supplemental Content

Loading ...
Support Center